Document Detail


10th anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit. 20-21 March 2006, New Brunswick, USA.
MedLine Citation:
PMID:  16732722     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The meeting was hosted by the Strategic Research Institute (SRi) celebrating its 10th anniversary of meetings targeting the inflammatory response. Entitled the 10th International Inflammation and Immune Diseases Drug Discovery and Development World Summit, it was held in New Brunswick, USA on 20-21 March 2006. A composition of keynote sessions and two parallel tracks, the meeting drew on the wide-ranging application of targeting drugs that modulate the immune response and have anti-inflammatory activity in a number of human diseases, including psoriasis, actinic keratosis, allergic dermatitis, rheumatoid and osteoarthritis, systemic lupus erythematosus, asthma and chronic obstructive pulmonary disease. Data were presented supporting all stages of drug discovery from target identification and validation through to lead identification and optimisation to both early- and late-stage clinical development. In addition, a number of enabling technologies were described that supported the identification of potential new therapeutics, for tracking antigen-specific B- and T cells through to the development of an immune response and for the development of novel delivery vehicles as a route to minimise toxicity profiles.
Authors:
Martin Braddock; Clare Murray
Publication Detail:
Type:  Congresses    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  15     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-05-30     Completed Date:  2007-10-26     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  721-7     Citation Subset:  IM    
Affiliation:
Discovery Bioscience, AstraZeneca R&D Charnwood,Bakewell Road, Loughborough, LE11 5RH, Leicestershire, England, UK. martin.braddock@astrazeneca.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Inflammatory Agents / administration & dosage*,  chemistry,  therapeutic use*
Asthma / drug therapy*,  metabolism
Clinical Trials as Topic
Drug Delivery Systems*
Drug Design
Drug Evaluation, Preclinical
Humans
JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors,  metabolism
Lupus Erythematosus, Systemic / drug therapy*,  metabolism
Nanotechnology
Protein Kinase Inhibitors / administration & dosage,  chemistry,  therapeutic use
Pulmonary Disease, Chronic Obstructive / drug therapy*,  metabolism
Receptors, Chemokine / antagonists & inhibitors,  metabolism
Technology, Pharmaceutical / methods
Thalidomide / administration & dosage,  analogs & derivatives,  chemistry,  therapeutic use
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Protein Kinase Inhibitors; 0/Receptors, Chemokine; 50-35-1/Thalidomide; EC 2.7.11.24/JNK Mitogen-Activated Protein Kinases; UP7QBP99PN/apremilast

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lonafarnib in cancer therapy.
Next Document:  The purine metabolism of human erythrocytes.